United States-based Merck's Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) plus platinum chemotherapy has improved overall survival and progression-free
survival of a certain type of lung cancer patients in a phase three trial, it was reported yesterday.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-189 trial investigating KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in combination with pemetrexed (Alimta) and cisplatin or carboplatin, for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), met its dual primary endpoints of overall survival (OS) and progression-free
Merck announced that the pivotal Phase 3 KEYNOTE-189 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with pemetrexed and cisplatin or carboplatin, for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, met its dual primary endpoints of overall survival and progression-free
The primary endpoint was the best objective response, and secondary endpoints included progression-free
and overall survival.
The primary endpoint was Clinical Benefit defined as remaining progression-free
by RECIST and Prostate Specific Antigen after treatment for 12+ weeks.
After initiation of metformin therapy, 36% of the group was progression-free
at 12 weeks, and 9% were still progression-free
at 24 weeks.
By combining the test drug, with the standard drug, we demonstrated a dramatic and clinically meaningful effect on progression-free
survival in women with ER+ advanced breast cancer," researchers said.
The primary end point was progression-free
Both trials were powered to detect an improvement in progression-free
survival, not overall survival.
The study was designed to measure progression-free
survival, the time a patient lived without the cancer progressing.
ORLANDO - Neoadjuvant chemotherapy with interval debulking surgery yields similar overall and longer progression-free
survival when compared with primary debulking surgery for women with stage IV epithelial ovarian cancer, according to a retrospective study.
A new treatment combining doxorubicin plus sorafenib has shown significant progression-free
and overall survival advantages over doxorubicin alone for patients with advanced hepatocellular cancer (HCC).